Allena Pharmaceuticals, Inc. EBIT Margin

EBIT Margin of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT Margin growth rates and interactive chart. Earnings before interest and taxes margin is an indicator of a company's profitability. Calculated as earnings before interest and taxes (EBIT) divided by revenue. It is useful for comparison of companies with different debt levels and tax rates. And EBIT margin gives a clear picture about the underlying profitability of a company's core operations. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes.

Highlights and Quick Summary

  • EBIT Margin for the quarter ending March 31, 2022 was 0.0% (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly EBIT Margin decreased by NaN%
  • Annual EBIT Margin for 2021 was 0.0% (a NaN% decrease from previous year)
  • Annual EBIT Margin for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual EBIT Margin for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month EBIT Margin ending March 31, 2022 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing EBIT Margin decreased by NaN% year-over-year
Trailing EBIT Margin for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT Margin of Allena Pharmaceuticals, Inc.

Most recent EBIT Marginof ALNA including historical data for past 10 years.

Interactive Chart of EBIT Margin of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. EBIT Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0% – – – –
2021 0.0% 0.0% 0.0% 0.0% 0.0%
2020 0.0% 0.0% 0.0% 0.0% 0.0%
2019 0.0% 0.0% 0.0% 0.0% 0.0%
2018 0.0% 0.0% 0.0% 0.0% 0.0%
2017 0.0% 0.0% 0.0% 0.0% 0.0%
2016 – – – 0.0% 0.0%
2015 – – – – 0.0%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
© stockrow.com